Shanghai Kechow Pharma, Inc. was established in 2014. It is a new drug R&D company integrating drug discovery, clinical development, and sales. Focused on independent R&D and scientific innovation, it is committed to addressing global unmet clinical needs
Exciting News! First Domestically Developed MEK Inhibitor Kolupin (Tunlametinib) Receives NMPA Approval for Market Release
Kechow Pharma is dedicated to developing innovative drugs in the therapeutic areas of oncology and free radical-related diseases. All of our research and development projects focus on original, new drugs with new compound structures, addressing the unmet clinical needs of patients in China and globally.
As a pharmaceutical company specializing in cancer treatment, Kechow Pharma has developed a unique R&D pipeline driven by its deep knowledge and understanding of oncology.
At Kechow, we believe that talents are our most valuable asset. We work with exceptional experts, industry professionals, and leading biopharmaceutical partners from around the world to bring the most advanced therapeutic drugs to China and the world.
